Accessibility Menu
PsyBio Therapeutics logo

PsyBio Therapeutics(OTC) PSYBF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
PsyBio Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-21
PsyBio Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-05-13
1 month+0%USD 0.002026-05-13
3 month+0%USD 0.002026-04-21
Year to date+0%USD 0.002025-12-22
1 year+0%USD 0.002025-05-13
3 year-100%USD 0.022023-07-21
5 year-100%USD 0.322021-07-22
Since inception-100%USD 0.302021-04-23

PsyBio Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.86M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-3.28 (Low)

Price

$0.00

Volume

12,510

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

PSYBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PsyBio Therapeutics

PsyBio Therapeutics Corp is a biotechnology company focused on developing innovative drugs aimed at treating mental health challenges and other disorders. Founded in 2009 and headquartered in Sunrise, Florida, the company is dedicated to advancing therapeutic solutions in the healthcare sector.

Products and Services
  • Development of psychedelic-based therapeutics for mental health
  • Research initiatives targeting various psychological disorders
  • Collaboration with academic institutions for drug development
Growth Outlook
  • Increasing global demand for mental health treatments drives market potential
  • Strategic partnerships enhance research capabilities and product development
  • Focus on regulatory approvals may lead to significant market entry opportunities
Financial Highlights
  • Q2 2023 net income of -$182,000 reflects ongoing investment in R&D
  • Trailing twelve months (TTM) cash flow from operations shows a negative trend
  • Current liabilities significantly exceed current assets, indicating liquidity challenges
PsyBio Therapeutics Corp is positioned in a rapidly evolving sector, with a focus on addressing critical mental health issues through innovative drug development. The company's commitment to research and collaboration with academic institutions may enhance its ability to bring new therapies to market. However, financial metrics indicate challenges, particularly in liquidity, as current liabilities surpass current assets. The ongoing investment in research and development is essential for future growth, but potential investors should consider the financial landscape and market dynamics before making decisions.
AI Generated • Aug 17, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Evan Levine

Headquarters

Denver, CO 80203, US

PSYBF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-867.29%

Return on Capital

N/A

Return on Assets

-1251.65%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

12.51K

Avg. Volume

273.594

Financials (TTM)

Gross Profit

-$88.08K

Operating Income

-$2.74M

EBITDA

-$2.71M

Operating Cash Flow

-$889.77K

Capital Expenditure

$0.00

Free Cash Flow

-$889.77K

Cash & ST Invst.

$12.37K

Total Debt

$96.14K

PsyBio Therapeutics Performance Analysis

PsyBio Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
PsyBio Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30N/A
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
PsyBio Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.10N/A
20222022-12-31USD -0.04-57.6%
PsyBio Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-3017.0%
Q42022-12-31-80.7%
Q12023-03-3133.3%
Q22023-06-3086.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$25.00K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

118

N/A

Net Income

-$182.00K

+87.3%

EBITDA

-$162.99K

+88.3%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$12.37K

-98.6%

Total Debt

$96.14K

-53.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$96.14K

-36.8%

Return on Assets

-12.52%

N/A

Return on Invested Capital

2.73%

N/A

Free Cash Flow

$339.60K

+126.0%

Operating Cash Flow

$339.60K

+126.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RLFTFMindMaze Therapeutics Holding S.A.
$0.22-15.85%
ACHFFArch Biopartners Inc.
$0.69-7.39%
OTLCOncotelic Therapeutics, Inc.
$0.03-15.21%
INNMFAmplia Therapeutics Limited
$0.10+5.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$105.03+0.10%
NOKNokia
$10.75+0.07%
NVDANvidia
$226.13-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.75+0.07%

Questions About PSYBF

What is the current price of PsyBio Therapeutics?

PsyBio Therapeutics is trading at $0.00 per share.

What is the 52-week range for PsyBio Therapeutics?

Over the past 52 weeks, PsyBio Therapeutics has traded between $0.00 and $0.00.

How much debt does PsyBio Therapeutics have?

As of the most recent reporting period, PsyBio Therapeutics reported total debt of $135.49K.

How much cash does PsyBio Therapeutics have on hand?

PsyBio Therapeutics reported $157.26K in cash and cash equivalents in its most recent financial results.

What is PsyBio Therapeutics’s dividend yield?

PsyBio Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services